- Home
- CCO vs PCRX Comparison
CCO vs PCRX Comparison
Compare CCO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCO
- PCRX
- Stock Information
- Founded
- CCO 1995
- PCRX 2006
- Country
- CCO United States
- PCRX United States
- Employees
- CCO N/A
- PCRX N/A
- Industry
- CCO Advertising
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CCO Consumer Discretionary
- PCRX Health Care
- Exchange
- CCO Nasdaq
- PCRX Nasdaq
- Market Cap
- CCO 576.2M
- PCRX 1.2B
- IPO Year
- CCO 2005
- PCRX 2011
- Fundamental
- Price
- CCO $1.23
- PCRX $22.90
- Analyst Decision
- CCO Buy
- PCRX Buy
- Analyst Count
- CCO 4
- PCRX 8
- Target Price
- CCO $1.88
- PCRX $28.38
- AVG Volume (30 Days)
- CCO 5.0M
- PCRX 525.8K
- Earning Date
- CCO 08-05-2025
- PCRX 07-29-2025
- Dividend Yield
- CCO N/A
- PCRX N/A
- EPS Growth
- CCO N/A
- PCRX N/A
- EPS
- CCO N/A
- PCRX N/A
- Revenue
- CCO $1,512,570,000.00
- PCRX $702,772,000.00
- Revenue This Year
- CCO $5.10
- PCRX $7.92
- Revenue Next Year
- CCO $3.29
- PCRX $11.02
- P/E Ratio
- CCO N/A
- PCRX N/A
- Revenue Growth
- CCO 14.28
- PCRX 3.08
- 52 Week Low
- CCO $0.81
- PCRX $11.16
- 52 Week High
- CCO $1.88
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- CCO 56.51
- PCRX 35.82
- Support Level
- CCO $1.18
- PCRX $22.82
- Resistance Level
- CCO $1.28
- PCRX $23.83
- Average True Range (ATR)
- CCO 0.06
- PCRX 0.74
- MACD
- CCO 0.00
- PCRX -0.02
- Stochastic Oscillator
- CCO 65.79
- PCRX 6.22
About CCO Clear Channel Outdoor Holdings Inc.
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.